{
 "topic": "Neurofibromatosis Type 1",
 "slug": "neurofibromatosis-type-1",
 "category_id": 15469,
 "summary": "NF1: the 2-of-7 clinical diagnostic criteria and their typical age of appearance, NF1 gene/neurofibromin genetics, and the periodic-monitoring approach to its unpredictable complications (optic glioma, learning disability, moyamoya).",
 "written_by": "claude-sonnet",
 "references": [
  {
   "title": "Pediatric Clinical Practice Guidelines and Policies",
   "author": "American Academy of Pediatrics (AAP);",
   "pages": [
    1295
   ]
  },
  {
   "title": "Pediatric Clinical Practice Guidelines & Policies, 18th Edition",
   "author": "American Academy of Pediatrics",
   "pages": [
    1269
   ]
  },
  {
   "title": "MedStudy Pediatrics Core 11th Edition 2024-2025",
   "author": null,
   "pages": [
    974,
    975
   ]
  },
  {
   "title": "CURRENT Diagnosis and Treatment Pediatrics, Twenty-Fourth Edition",
   "author": "Hay, William W., Levin, Myron J., Deterding, Robin R., Abzug, Mark J.",
   "pages": [
    821,
    1143
   ]
  },
  {
   "title": "Cover",
   "author": "Vitalsource Download",
   "pages": [
    2645,
    2646
   ]
  },
  {
   "title": "Netters Pediatrics (Florin Т., Ludwig St.)",
   "author": null,
   "pages": [
    505,
    789
   ]
  },
  {
   "title": "Kliegman R. Nelson Textbook of Pediatrics 2-Volume Set 22ed 2024",
   "author": null,
   "pages": [
    3690
   ]
  },
  {
   "title": "Diagnostic Imaging: Pediatrics",
   "author": "A. Carlson Merrow Jr. MD",
   "pages": [
    1055
   ]
  }
 ],
 "short": [
  {
   "title": "In short",
   "content": "- Neurofibromatosis type 1 (NF1, formerly von Recklinghausen disease) is the most common neurocutaneous disorder and one of the most common autosomal dominant conditions, with prevalence estimates of about 1 in 2,500-3,500 (commonly cited as 1 in 3,000).\n- Caused by loss-of-function mutations in the NF1 gene on chromosome 17q11.2, encoding neurofibromin (a RAS GTPase-activating protein and tumor suppressor); about 50% of cases are inherited from an affected parent and 50% are new (sporadic) mutations; penetrance is close to 100% with careful examination.\n- Diagnosis requires 2 of 7 criteria: (1) 6 or more cafe-au-lait macules (over 5 mm in prepubertal, over 15 mm in postpubertal individuals); (2) 2 or more neurofibromas of any type, or 1 plexiform neurofibroma; (3) axillary or inguinal freckling; (4) optic pathway glioma; (5) 2 or more Lisch nodules (iris hamartomas); (6) a distinctive osseous lesion (e.g., sphenoid dysplasia, tibial pseudoarthrosis/long-bone cortex thinning); (7) a first-degree relative with NF1.\n- Cafe-au-lait macules are present in almost 100% of patients, usually from birth, increasing in size/number/pigmentation especially in the first few years of life; axillary/inguinal freckling appears by adolescence in about 75% of cases; Lisch nodules are seen on slit-lamp exam in about 75% of prepubescent children (usually after age 3).\n- Optic pathway gliomas occur in about 15-20% of children with NF1, most often under age 6, and can cause visual loss or precocious puberty - refer to ophthalmology whenever NF1 is suspected.\n- Children with 6 or more cafe-au-lait spots and no other criteria should be followed, since about 95% go on to develop full NF1; most children meet formal diagnostic criteria by 8-10 years of age.\n- About two-thirds of NF1 patients have manifestations that generally do not require clinical intervention, while the remaining third experience a range of medical complications, unpredictable in timing and severity (roughly 40% develop complications over a lifetime).\n- Learning disability related to NF1 occurs in 30-60% of affected children; vascular dysplasia (moyamoya arteriopathy) occurs in 3-7% of children with NF1. Notably, optic pathway and brainstem gliomas behave more indolently in NF1 patients than in those without NF1.\n"
  }
 ],
 "long": [
  {
   "title": "Definition",
   "content": "Neurofibromatosis type 1 (NF1) is a multisystem disorder primarily involving the skin and peripheral/central nervous system, historically called von Recklinghausen disease. It is distinct from neurofibromatosis type 2 (NF2), which is characterized by bilateral acoustic neuromas with minimal or no skin manifestations and is caused by a different gene.\n"
  },
  {
   "title": "Epidemiology",
   "content": "NF1 is the most common neurocutaneous disorder and one of the most common autosomal dominant conditions, with population prevalence estimated between about 1 in 2,500 and 1 in 3,500 (most commonly cited as 1 in 3,000), affecting all races and ethnic groups. The condition is usually recognized in early childhood, when pigmentary (cutaneous) manifestations become apparent.\n"
  },
  {
   "title": "Etiology",
   "content": "NF1 results from autosomal dominant loss-of-function pathogenic variants in the NF1 gene, located on the long arm of chromosome 17 (17q11.2), which encodes neurofibromin, a RAS GTPase-activating protein that functions as a tumor suppressor. Approximately 50% of cases are inherited from an affected parent, and the other 50% arise from new (sporadic) mutations, so careful evaluation of parents is necessary for accurate genetic counseling. Penetrance is close to 100% in gene carriers when examined carefully, though clinical expression is highly variable.\n"
  },
  {
   "title": "Clinical Features",
   "content": "NF1 is associated with marked clinical variability. Some features are present at birth, while others are age-related and emerge over time, requiring periodic monitoring. Cafe-au-lait macules (CALMs) are the hallmark feature, present in almost 100% of patients; they are present at birth but increase in size, number, and pigmentation especially during the first few years of life, typically scattered over the trunk and extremities. Axillary or inguinal freckling appears by adolescence in about 75% of cases. Lisch nodules (benign iris hamartomas) are identified by slit-lamp exam in about 75% of prepubescent children, usually appearing after age 3. Neurofibromas (benign peripheral nerve sheath tumors composed of Schwann cells) typically appear later, usually after age 7, often in late adolescence; plexiform neurofibromas can appear anywhere from birth to age 18. Optic pathway gliomas occur in 15-20% of children with NF1, most often before age 6 (though can occur up to age 30), and can cause visual loss or precocious puberty; orbital plexiform neurofibromas are associated with sphenoid wing defects. Vascular dysplasia (moyamoya arteriopathy), with narrowing of vessels (especially the distal internal carotid artery) and collateral formation, occurs in 3-7% of children with NF1. Approximately two-thirds of individuals with NF1 have manifestations that generally do not require clinical intervention, while the remaining third experience a range of medical complications unpredictable in both timing and severity; overall, about 40% of patients develop medical complications over their lifetime. NF1-related learning disability occurs in 30-60% of affected children. Despite the range of possible complications, most children with NF1 follow patterns of growth and development within the normal range.\n"
  },
  {
   "title": "Diagnostics",
   "content": "Diagnosis is clinical, requiring at least 2 of 7 criteria (updated by international expert panel in 2021): (1) 6 or more cafe-au-lait macules greater than 5 mm in greatest diameter in prepubertal individuals, or greater than 15 mm in postpubertal individuals; (2) 2 or more neurofibromas of any type, or 1 plexiform neurofibroma; (3) freckling in the axillary or inguinal region; (4) optic pathway glioma; (5) 2 or more Lisch nodules (iris hamartomas); (6) a distinctive osseous lesion, such as sphenoid dysplasia or long-bone cortex thinning with or without pseudoarthrosis; (7) a first-degree relative (parent, sibling, or child) with NF1 by these same criteria. Cafe-au-lait macules are not specific to NF1 and can be seen in other conditions such as McCune-Albright syndrome and Russell-Silver syndrome. Most children meet formal diagnostic criteria by 8-10 years of age. A child with 6 or more cafe-au-lait spots but no other diagnostic criterion should be followed clinically, since about 95% eventually develop full NF1. Any suspicion of NF1 warrants ophthalmology referral, given the risk of optic pathway glioma and Lisch nodules.\n"
  },
  {
   "title": "Treatment",
   "content": "Because manifestations emerge over time and complications are unpredictable, periodic monitoring is central to management, aiming to address ongoing health and developmental needs and minimize the risk of serious medical complications. Management is otherwise directed at specific complications as they arise (for example, ophthalmologic follow-up for optic pathway glioma, and attention to learning difficulties given their high prevalence in this population).\n"
  },
  {
   "title": "Complications",
   "content": "Recognized complications include optic pathway and other CNS gliomas (which behave more indolently in NF1 patients than in those without NF1), plexiform neurofibromas (which can be locally infiltrative), osseous lesions such as sphenoid dysplasia or tibial pseudoarthrosis, vascular dysplasia (moyamoya arteriopathy) in a minority of patients, and learning disability in 30-60% of affected children. The overall unpredictability of complication timing and severity is a defining clinical challenge in managing NF1.\n"
  }
 ],
 "clinical": [
  {
   "title": "Diagnosing NF1 in a Child",
   "content": "Apply the 2-of-7 criteria systematically: 6 or more cafe-au-lait macules (over 5 mm prepubertal, over 15 mm postpubertal), 2 or more neurofibromas of any type or 1 plexiform neurofibroma, axillary/inguinal freckling, optic pathway glioma, 2 or more Lisch nodules, a distinctive osseous lesion, or a first-degree relative with NF1. Expect cafe-au-lait macules from birth, freckling by adolescence in about 75% of cases, and Lisch nodules on slit-lamp exam in about 75% of prepubescent children after age 3 - so a young child may only show cafe-au-lait spots initially. When a child has 6 or more cafe-au-lait macules but no other criterion yet, do not dismiss NF1 - follow the child clinically, since about 95% eventually meet full diagnostic criteria (usually by 8-10 years of age). Refer to ophthalmology for slit-lamp exam and screening whenever NF1 is suspected or diagnosed, given the risk of Lisch nodules and, more importantly, optic pathway glioma (occurring in 15-20% of NF1 children, usually before age 6), which can cause visual loss or precocious puberty. When counseling families, evaluate both parents carefully, since about half of cases are inherited (autosomal dominant, nearly full penetrance) and half are new mutations - this distinction matters for genetic counseling of the family.\n"
  },
  {
   "title": "Monitoring for Complications",
   "content": "Set expectations that NF1 manifestations emerge over time rather than all at once, and that about two-thirds of patients have a mild course while the remaining third face a range of unpredictable complications - so periodic, structured monitoring (rather than one-time reassurance) is the right model of care. Screen for and address learning disability actively, since it affects 30-60% of children with NF1 and is a major driver of quality of life, independent of physical manifestations. Watch for signs of vascular dysplasia (moyamoya arteriopathy, in 3-7% of children) if new neurologic symptoms develop, and remember that optic pathway and brainstem gliomas in NF1 tend to behave more indolently than in children without NF1, which can inform a more conservative initial approach to management in consultation with neuro-oncology.\n"
  }
 ]
}